Insulin pens are used by millions of people to control blood pressure and manage diabetes.
First introduced by Danish pharmaceutical tech company Novo Nordisk in 1985, an insulin pen is an injectable solution of insulin that's used to treat diabetes. Our bodies produce some insulin naturally in the pancreas. People who suffer from diabetes, however, may require additional insulin to better manage their blood-sugar levels and protect against diabetic shock. This has led to other companies entering the insulin pen market, releasing and selling their own injectable insulin products.
Most insulin pens fall under one of two categories: durable or pre-filled. A durable pen uses replacement insulin cartridges, so once the patient has used the device, he or she can discard the insulin cartridge and replace it with a new one. On the other hand, a prefilled pen is a one-time-use device. Once the patient has used the injectable insulin, he or she must buy a completely new insulin pen.
According to Wikipedia, insulin pens are used by 95% of insulin-treated patients in Europe, Asia and Australia. While they are still used in the United States, the market is still gaining momentum.
The Global Insulin Pens and Needles Market Research 2016 report by The Market Reports is an in-depth report on the global insulin pens and needles market. Featuring more than 150 tables and figures, along with key statistics and industry forecast trends, it's a comprehensive report on the world's global insulin pens and needles market. It reveals the market's development policies and plans, manufacturing processes, Bill of Materials, import/export consumption, supply and demand, cost, price, revenue, gross margins and more.
Some of the insulin pens and needles vendors profiled in this report include Novo Nordisk, Becton, BD, Dickinson, Ypsomed Holdings, Owen Mumford, HTL-STREFA, B. Braun Melsungen, Terumo Corporation, Allison Medical, Artsana S.p.a., and UltiMed.
The Human Insulin Market - Drugs (Biol…Forecasts to 2020 report by RNR Market Research is a second comprehensive report on the global insulin market. According to this report, the human insulin market is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2015 to 2020. While there are many different factors driving this growth, some of the most influential include increasing exposure to diabetes risk factors, rising market demand for insulin analogs, technological advancements in human insulin delivery, and positive medical reimbursements. With that said, there are certain restraints faced by the insulin market, such as the high cost of manufacturing.